emavusertib (CA-4948) / Curis, Dr. Reddy’s  >>  Phase 2
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
emavusertib (CA-4948) / Curis, Dr. Reddy’s
2020-003986-20: Treatment of anemia with CA-4948 in very low, low, or intermediate risk MDS patients. Behandlung einer Anämie mit CA-4948 bei MDS Patienten mit sehr niedrigem, niedrigem oder mittlerem Risiko.

Not yet recruiting
2
84
Europe
Emavusertib, CA-4948, Film-coated tablet
Leipzig University, Curis, Inc
Anemia in patients with very low, low or intermediate risk myelodysplastic syndromes (MDS) Anämie bei Patienten mit myelodysplastischen Syndromen (MDS) mit sehr niedrigem, niedrigem oder mittlerem Risiko, Anemia Anämie, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
LUCAS, NCT05178342: Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

Terminated
2
38
Europe
CA-4948, Emavusertib
University of Leipzig, Curis, Inc.
Myelodysplastic Syndromes, Anemia
03/24
03/24
2022-000891-20: An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Hematologic Malignancies Estudio abierto, con escalado de dosis y expansión de dosis, para evaluar la seguridad, la farmacocinética, la farmacodinámica y la actividad clínica del CA‑4948 administrado por vía oral en pacientes con neoplasias hematológicas en recaída o refractarias

Not yet recruiting
1/2
221
Europe
Ibrutinib, CA-4948, Film-coated tablet, Imbruvica
Curis, Inc., Curis, Inc.
Relapsed or Refractory Hematologic Malignancy Neoplasias hematológicas en recaída o refractarias, Relapsed or Refractory Hematologic Malignancy Neoplasias hematológicas en recaída o refractarias, Diseases [C] - Cancer [C04]
 
 
2019-004839-23: Study of Orally Administered CA-4948(IRAK4i) as a Monotherapy in patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination with Azacitidine or Venetoclax Estudio para evaluar CA-4948 (IRAK4i) administrado por vía oral en pacientes con leucemia mielógena aguda o síndrome mielodisplásico tanto en monoterapia como en combinación con azacitidina o venetoclax

Not yet recruiting
1/2
366
Europe
CA-4948, Film-coated tablet
Curis, Inc, Curis, Inc
Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). leucemia mielógena aguda(LMA) o alto riesgo de síndrome mielodisplásico(SDM)., AML: cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are madeMDS: group of disorders caused by poorly formed blood cells or ones that don't work properly LMA:Cancer sanguineo y medula osea SDM: grupo de trastornos causados por células sanguíneas mal formadas o que no funcionan correctamente, Diseases [C] - Cancer [C04]
 
 
CA-4948-102, NCT04278768: Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS

Recruiting
1/2
366
Europe, US, RoW
Emavusertib, CA-4948, Venetoclax
Curis, Inc.
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
04/26
04/26
CA-4948-101, NCT03328078: A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Hourglass Apr 2021 - Sep 2021 : Early data from trial in combination with CA-4948 for r/r NHL
Checkmark From dose escalation study in patients with DH/DE DLBCL
Dec 2019 - Dec 2019: From dose escalation study in patients with DH/DE DLBCL
Checkmark Data from r/r NHL, DLBCL, Waldenström's macroglobulinemia and oncogenic MYD88 mutations
Dec 2019 - Dec 2019: Data from r/r NHL, DLBCL, Waldenström's macroglobulinemia and oncogenic MYD88 mutations
More
Recruiting
1/2
80
Europe, US, RoW
Emavusertib, CA-4948, ibrutinib
Curis, Inc.
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
08/26
08/26
NCT05669352: A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab Following Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

Recruiting
1/2
29
US
CA-4948, Pembrolizumab
University of Florida, Merck Sharp & Dohme LLC
Melanoma Metastatic in the Brain
08/26
08/27

Download Options